Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.85 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.85 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | IGF1R | P08069 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955199 | 0.94 | EGFR (0.88) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL22955045 | 0.94 | EGFR (0.87) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL19095645 | 0.92 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Mobocertinib SCHEMBL30531221 | 0.92 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Mobocertinib SCHEMBL17373133 | 0.92 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Mobocertinib SCHEMBL30531240 | 0.92 | EGFR (0.99) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Mobocertinib SCHEMBL30531258 | 0.92 | EGFR (0.99) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL19095675 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Mobocertinib SCHEMBL30531218 | 0.90 | EGFR (0.96) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL19095659 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-4006014-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | Medshine Discovery Inc. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018017-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885ERBB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.